- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02453646
Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a U.S. multi - centre, prospective, non-randomized post approval registry. Approximately one hundred and twenty patients will be implanted with a NexSite HD catheter at four to eight U.S. sites where hemodialysis catheters are routinely implanted. Each site may enrol a maximum of 50 patients. Enrolled patients will be followed from device placement to device removal or 180 days post device placement. Patients will be enrolled once only.
The primary endpoint is CRBSI rate related to the NexSite HD catheter. Determination of infection will be decided by the investigator and if necessary adjudicated by the CEC (Clinical Events Committee) based on blood culture results, regardless of whether the catheter is removed.
Secondary endpoints for the study are
- Successful placement and continued use of the NexSite HD device designed for use in patients requiring long term hemodialysis.
- Healing of catheter exit site
- Tunnel Infections
- Exit site infections
- Early non-infectious complications associated with CVCs
- Late non-infectious complications associated with Central Venous Catheters
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
North Carolina
-
Greenville, North Carolina, Verenigde Staten, 27834
- Eastern Nephrology Associates
-
New Bern, North Carolina, Verenigde Staten, 28542
- Eastern Nephology Associates
-
Raleigh, North Carolina, Verenigde Staten, 27610
- Capital Nephrology Associates
-
-
South Carolina
-
Orangeburg, South Carolina, Verenigde Staten, 29118
- South Carolina Nephrology and Hypertension Center Inc
-
-
Texas
-
Lubbock, Texas, Verenigde Staten, 79416
- Lubbock Vascular Access Centre
-
San Antonio, Texas, Verenigde Staten, 78215
- Renal Associates
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- The patient shall be 18 - 80 years old.
- The patient requires the placement of a long term tunnelled HD catheter for administration of hemodialysis.
- The patient has anticipated survival in excess of 90 days from the anticipated date of catheter placement.
- The patient has the ability to understand the research subject information and sign a written Informed Consent form which must be obtained prior to initiation of the study.
- The patient receives the catheter via the internal jugular or subclavian vein.
- All female patients of child bearing potential must complete a negative pregnancy test and will confirm that they are not breastfeeding.
Exclusion Criteria:
- The patient is participating in another IRB (Institutional Review Board) clinical trial, which modifies standard-of-care treatment and/or involves an investigational device or drug.
- The patient has a confirmed or suspected infection, bacteraemia or septicaemia.
- The patient's physiology is NOT suitable for placement of the NexSite device; this will include an examination of the anatomy at the proposed catheter exit site.
- The patient is known or suspected to have allergies to the materials used in the construction of the device.
- The patient has previously suffered from coagulation issues or has had vascular surgery at the proposed placement site.
- The patient has received radiation treatment at the proposed catheter placement site.
- The patient has severe chronic obstructive lung disease.
- The patient is pyretic within 72 hours (temperature ≥38o C or 100.4oF) prior to placement and/or has received antimicrobial drugs within two weeks prior to catheterisation.
- The patient is female of child bearing potential not using adequate contraception. (Adequate contraception is defined as abstinence, intrauterine device [IUD], birth control pills, or spermicidal gel with diaphragm or condom)
- The patient has another indwelling catheter.
- The patient has non-healing diabetic foot ulcers.
- The patient did not give informed consent.
- The patient would be unavailable for follow-up.
- The patient is a permanent nursing home resident.
- The proposed access site is not the internal jugular or subclavian vein.
- The patient is scheduled to undergo an elective surgical procedure (other than a procedure to create a graft or fistula) within the study timeframe.
- Any other condition that the Investigator believes should exclude the patient from the study.
- The patient does not have English or Spanish as their first language.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: NexSite HD Patients
NexSite HD patient catheter device placement
|
Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants with Catheter-Related Blood Stream Infection (CRBSI)(bacteremia/fungemia) as an adverse event.
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with a confirmed CRBSI for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants with adverse events associated with device placement and use.
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with adverse events associated with device placement and for the duration of catheter use or to 180 days post device placement.
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with unhealed catheter exit sites
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with unhealed exit sites for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with tunnel infection as an adverse event
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with a tunnel infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with exit site infection as an adverse event
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with a exit site infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with Pneumothorax, haemothorax, arrhythmia, air embolism or arterial perforation as an adverse event.
Tijdsspanne: 1 day of device placement
|
Number of participants with non-infectious catheter complications within one day of placement.
|
1 day of device placement
|
|
Number of participants with Catheter dislodgement, Catheter tip dislodgement and catheter thrombosis as an adverse event.
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with late non infectious complications for the duration of catheter use or to 180 days post device placement (whichever occurs first).
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Jeffrey G Hoggard, MD, Capital Nephrology Associates
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TR 0147
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Eindstadium nierziekte
-
The Third Xiangya Hospital of Central South UniversityVoltooidEvaluation of the Application of Intelligent Applications in Patients Undergoing Peritoneal DialysisESRD (End-Stage Renal Disease) | Nierfalen chronischChina
-
Bristol-Myers SquibbVoltooidTrombose | Nierfunctiestoornis | Factor XI | ESRD (End-Stage Renal Disease)Verenigde Staten
-
United TherapeuticsWervingNiertransplantatie | ESRD (End-Stage Renal Disease) | XenotransplantatieVerenigde Staten
-
Buddhist Tzu Chi General HospitalMultipower Enterprise Corp.Nog niet aan het wervenDialyse | ESRD (End-Stage Renal Disease)
-
United TherapeuticsWervingNiertransplantatie | ESRD (End-Stage Renal Disease) | XenotransplantatieVerenigde Staten
-
Alebund PharmaceuticalsFortreaWervingHyperfosfatemie | Dialyse | ESRD (End-Stage Renal Disease) | Chronische nierziekte, dialyse ondergaanChina, Verenigde Staten
Klinische onderzoeken op NexSite HD Patients
-
Boston Medical CenterNortheastern UniversityVoltooidPreconceptie zorgVerenigde Staten
-
Medical University of South CarolinaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); University of Alabama at BirminghamVoltooid
-
University of CalgaryVoltooidOntstekingsdarmziekteCanada
-
Ariel UniversityTel Aviv UniversityVoltooid
-
Alvotech Swiss AGWerving
-
The University of QueenslandCanadian Institutes of Health Research (CIHR); Queensland Health; Medical Research...WervingNierfalenAustralië, Canada
-
The University of Texas at DallasVoltooidGezonde volwassenenVerenigde Staten
-
National Taiwan University HospitalWerving
-
Hasan Kalyoncu UniversityVoltooidOngerustheid | Pijnbeheersing | Onvruchtbaarheid (IVF-patiënten)Turkije (Türkiye)
-
Shanghai Mental Health CenterChinese Academy of SciencesBeëindigd